million NIH grant, the preclinical biotech is developing a paired, fast-acting therapeutic and reversal agent for surgical and trauma patients." /> million NIH grant, the preclinical biotech is developing a paired, fast-acting therapeutic and reversal agent for surgical and trauma patients." /> million NIH grant, the preclinical biotech is developing a paired, fast-acting therapeutic and reversal agent for surgical and trauma patients." />